Focus: Cell therapy

Focus: Cell therapy 2018-06-28T10:39:22+00:00


Flemingsberg has a long history of outstanding research and clinical service, particularly in the field of cell therapy and regenerative medicine.

Evolving cell therapies gives hope of effective treatment of heart disease, autoimmune diseases such as diabetes, as well as cancer, Parkinson’s and Alzheimer’s disease. These therapies involves the use of cells to stimulate the body’s own repair mechanisms to combat the disease.

Developing new therapies
At Karolinska Institutet, scientists develop new concepts in stem cell biology with the goal to bring new therapies to patients in several disease areas. Karolinska Institutet has a broad range of infrastructures and core facilities.

Among those is Vecura a core facility at the Karolinska University Hospital Huddinge for production of gene therapy vectors and cell therapy products for clinical trials.

The facility is certified by the Swedish Medical Product Agency and the National Board of Health and Welfare. Vecura has been in operation since 1996 and has produced more than 30 GMP products including the first Swedish-made gene therapy vector and cell therapy product. The facility is of great importance for the development of regenerative medicine at Karolinska and in Sweden.

Flemingsberg is a part of Stockholm Life: a region with one of Europe’s highest densities of Life science companies, organizations and institutes. The Stockholm-Uppsala region hosts some 550 Life science companies. The industry in the region employs more than 20 000 people.

More local examples:

More on Scandinavia’s leading life-science cluster from Stockholm Business Region Development.

Report: Driving forces behind stem cell research in the Stockholm region. Read the report on entrepreneurship and commercialization in the Stockholm region: Background facts 2015, from Stockholm Business Region Development.

The Flemingsberg Science Foundation offers personal and tailored support to companies and organizations interested in collaborating with innovative Life science projects in Flemingsberg.

With Single Gene Insertion, Blind Mice Regain Sight [read more]

In Vivo Neuronal Gene Editing via CRISPR-Cas9 Amphiphilic Nanocomplexes Alleviates Deficits in Mouse [read more]

An Automated Hybrid Bioelectronic System for Autogenous Restoration of Sinus Rhythm in Atrial Fibril [read more]

Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immuno [read more]

Phase I Trial of an RNA Interference Therapy for Acute Intermittent Porphyria [read more]